CN114075190A - 杂环类btk抑制剂 - Google Patents

杂环类btk抑制剂 Download PDF

Info

Publication number
CN114075190A
CN114075190A CN202010836243.4A CN202010836243A CN114075190A CN 114075190 A CN114075190 A CN 114075190A CN 202010836243 A CN202010836243 A CN 202010836243A CN 114075190 A CN114075190 A CN 114075190A
Authority
CN
China
Prior art keywords
alkyl
room temperature
cycloalkyl
esi
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010836243.4A
Other languages
English (en)
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Priority to CN202010836243.4A priority Critical patent/CN114075190A/zh
Priority to JP2023512197A priority patent/JP7669063B2/ja
Priority to EP21857742.7A priority patent/EP4200283A4/en
Priority to PCT/CN2021/113538 priority patent/WO2022037650A1/en
Priority to JP2023512198A priority patent/JP2023538091A/ja
Priority to CN202180050894.3A priority patent/CN116670119B/zh
Priority to PCT/CN2021/113535 priority patent/WO2022037649A1/en
Publication of CN114075190A publication Critical patent/CN114075190A/zh
Priority to US18/169,423 priority patent/US20230192691A1/en
Priority to US18/169,408 priority patent/US12617788B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202010836243.4A 2020-08-20 2020-08-20 杂环类btk抑制剂 Pending CN114075190A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202010836243.4A CN114075190A (zh) 2020-08-20 2020-08-20 杂环类btk抑制剂
JP2023512197A JP7669063B2 (ja) 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての架橋二環式化合物
EP21857742.7A EP4200283A4 (en) 2020-08-20 2021-08-19 BRIDGED BICYCLIC COMPOUNDS AS BTK INHIBITORS
PCT/CN2021/113538 WO2022037650A1 (en) 2020-08-20 2021-08-19 Bridged bicyclic compounds as btk inhibitors
JP2023512198A JP2023538091A (ja) 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての複素環式化合物
CN202180050894.3A CN116670119B (zh) 2020-08-20 2021-08-19 作为btk抑制剂的桥联双环化合物
PCT/CN2021/113535 WO2022037649A1 (en) 2020-08-20 2021-08-19 Heterocyclic compounds as btk inhibitors
US18/169,423 US20230192691A1 (en) 2020-08-20 2023-02-15 Heterocyclic compounds as btk inhibitors
US18/169,408 US12617788B2 (en) 2020-08-20 2023-02-15 Bridged bicyclic compounds as BTK inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010836243.4A CN114075190A (zh) 2020-08-20 2020-08-20 杂环类btk抑制剂

Publications (1)

Publication Number Publication Date
CN114075190A true CN114075190A (zh) 2022-02-22

Family

ID=80282666

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010836243.4A Pending CN114075190A (zh) 2020-08-20 2020-08-20 杂环类btk抑制剂
CN202180050894.3A Active CN116670119B (zh) 2020-08-20 2021-08-19 作为btk抑制剂的桥联双环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180050894.3A Active CN116670119B (zh) 2020-08-20 2021-08-19 作为btk抑制剂的桥联双环化合物

Country Status (5)

Country Link
US (1) US20230192691A1 (https=)
EP (1) EP4200283A4 (https=)
JP (2) JP2023538091A (https=)
CN (2) CN114075190A (https=)
WO (2) WO2022037650A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114573586A (zh) * 2020-11-28 2022-06-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN114634512A (zh) * 2020-12-16 2022-06-17 江苏恒瑞医药股份有限公司 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
CN115443277A (zh) * 2020-03-12 2022-12-06 重庆复尚源创医药技术有限公司 作为激酶抑制剂的化合物
CN116693458A (zh) * 2022-03-03 2023-09-05 深圳市塔吉瑞生物医药有限公司 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
WO2025007863A1 (zh) * 2023-07-03 2025-01-09 深圳市塔吉瑞生物医药有限公司 1H-吡唑并[4,3-c]吡啶化合物及其组合物及用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2015132799A2 (en) * 2014-02-03 2015-09-11 Cadila Healthcare Limited Novel heterocyclic compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
JP7337502B2 (ja) * 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
AU2017383236B2 (en) * 2016-12-21 2022-02-10 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
WO2020015735A1 (zh) * 2018-07-20 2020-01-23 正大天晴药业集团股份有限公司 布鲁顿酪氨酸激酶抑制剂
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
CN113365631B (zh) * 2019-01-18 2024-08-30 杭州邦顺制药有限公司 布鲁顿酪氨酸激酶抑制剂
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443277A (zh) * 2020-03-12 2022-12-06 重庆复尚源创医药技术有限公司 作为激酶抑制剂的化合物
CN114573586A (zh) * 2020-11-28 2022-06-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN114634512A (zh) * 2020-12-16 2022-06-17 江苏恒瑞医药股份有限公司 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
CN114634512B (zh) * 2020-12-16 2023-11-14 江苏恒瑞医药股份有限公司 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
CN116693458A (zh) * 2022-03-03 2023-09-05 深圳市塔吉瑞生物医药有限公司 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
WO2023165570A1 (zh) * 2022-03-03 2023-09-07 深圳市塔吉瑞生物医药有限公司 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
WO2025007863A1 (zh) * 2023-07-03 2025-01-09 深圳市塔吉瑞生物医药有限公司 1H-吡唑并[4,3-c]吡啶化合物及其组合物及用途

Also Published As

Publication number Publication date
WO2022037650A1 (en) 2022-02-24
EP4200283A1 (en) 2023-06-28
JP2023538090A (ja) 2023-09-06
CN116670119A (zh) 2023-08-29
CN116670119B (zh) 2026-04-14
EP4200283A4 (en) 2024-10-23
JP2023538091A (ja) 2023-09-06
US20230192691A1 (en) 2023-06-22
WO2022037649A1 (en) 2022-02-24
US20230212175A1 (en) 2023-07-06
JP7669063B2 (ja) 2025-04-28

Similar Documents

Publication Publication Date Title
CN113286794B (zh) Kras突变蛋白抑制剂
CN114075190A (zh) 杂环类btk抑制剂
CA3042960C (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
CN101594871B (zh) 吡咯并嘧啶化合物及其用途
US8859569B2 (en) Substituted annellated pyrimidines and use thereof
EP4288435A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
TWI794232B (zh) 激酶抑制劑及其用途
CN105121443B (zh) 蛋白激酶抑制剂
CN115427035B (zh) Enl/af9 yeats抑制剂
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
WO2017128917A1 (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用
CN112979655A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
JP7663968B2 (ja) Ｗｄｒ５阻害剤及び調節剤
WO2022160931A1 (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
CN115124533A (zh) 四环类衍生物、其制备方法和其医药上的用途
CN120530110A (zh) 杂环化合物、药物组合物及其应用
JP2011519934A (ja) スピロアザインドール
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
CN114644633B (zh) 杂环类jak抑制剂
CN110540521A (zh) 八氢戊搭烯类化合物、其制备方法及其在医药学上的应用
US20240262822A1 (en) Wdr5 inhibitors and modulators
AU2004249629B2 (en) Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same
CN112384506B (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
HK40042275A (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK40042275B (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220222

WD01 Invention patent application deemed withdrawn after publication